AI Article Synopsis
- Motor and cognitive deficits in Parkinson's disease (PD) are often thought to stem from motivational issues, but recent research suggests that motivation for cognitive control may actually be heightened in PD patients.
- A study comparing PD patients with and without depression to age-matched healthy controls found that rewards improved task-switching abilities in PD patients, while it made task-switching worse for healthy controls.
- The results highlight that even though depression is common in PD, it did not impact cognitive performance, suggesting that incentive motivational strategies could be beneficial for addressing cognitive deficits in Parkinson's disease.
Article Abstract
Motor and cognitive deficits in Parkinson's disease (PD) have been argued to reflect motivational deficits. In prior work, however, we have shown that motivation of cognitive control is paradoxically potentiated rather than impaired in Parkinson's disease. This is particularly surprising given the fact that Parkinson's disease is often accompanied by depression, a prototypical disorder of motivation. To replicate our previous finding and assess the effects of depression, we investigated performance of PD patients with (n = 22) and without depression (history) (n = 23) and age-matched healthy controls (n = 23) on a task specifically designed to measure the effect of reward motivation on task-switching. We replicated previous findings by showing contrasting effects of reward motivation on task-switching in PD patients and age-matched healthy controls. While the promise of high versus low reward improved task-switching in PD, it tended to impair task-switching in age-matched healthy controls. There were no effects of a depression (history) diagnosis in PD patients. These findings reinforce prior observations that Parkinson's disease is accompanied by enhanced incentive motivation of cognitive control and highlight the potential of incentive motivational strategies for overcoming cognitive deficits in Parkinson's disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175070 | PMC |
| http://dx.doi.org/10.1111/ejn.14137 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Healthcare utilization and costs for patients with Parkinson's disease in Taiwan.
BMC Neurol
January 2025
Department of Public Health, College of Medicine, National Cheng Kung University, No.1, University Road, Tainan City, 701, Taiwan.
Background: Parkinson's disease (PD) exerts a considerable burden on the elderly. Studies on long-term costs for Parkinson's disease patients in Taiwan are not available.
Objectives: This study aims to examine the medical resource utilization and medical costs including drug costs for PD patients in Taiwan over up to 15 years of follow-up.
Exploring the stigma experienced by people affected by Parkinson's disease: a systematic review.
BMC Public Health
January 2025
School of Nursing and Midwifery, Queen's University Belfast, Belfast, Northern Ireland, UK.
Background: Stigma significantly impacts individuals with Parkinson's disease (PD) and their caregivers, exacerbating social isolation, psychological distress, and reducing quality of life (QoL). Although considerable research has been conducted on PD's clinical aspects, the social and emotional challenges, like stigma, remain underexplored. Addressing stigma is crucial for enhancing well-being, fostering inclusivity and improving access to care and support.
View Article and Find Full Text PDFA Wonderful Journey: The Diverse Roles of Adenosine Deaminase Action on RNA 1 (ADAR1) in Central Nervous System Diseases.
CNS Neurosci Ther
January 2025
Jiujiang Clinical Precision Medicine Research Center, Jiujiang, Jiangxi, China.
Background: Adenosine deaminase action on RNA 1 (ADAR1) can convert the adenosine in double-stranded RNA (dsRNA) molecules into inosine in a process known as A-to-I RNA editing. ADAR1 regulates gene expression output by interacting with RNA and other proteins; plays important roles in development, including growth; and is linked to innate immunity, tumors, and central nervous system (CNS) diseases.
Results: In recent years, the role of ADAR1 in tumors has been widely discussed, but its role in CNS diseases has not been reviewed.
Using a sex- and gender-informed lens to enhance care in Parkinson's disease.
Nat Med
January 2025
Women's Brain Foundation, Basel, Switzerland.
Space exploration and risk of Parkinson's disease: a perspective review.
NPJ Microgravity
January 2025
Department of Biological Science, Boise State University, Boise, ID, 83725, USA.
Systemic mitochondrial dysfunction, dopamine loss, sustained structural changes in the basal ganglia including reduced tyrosine hydroxylase, and altered gait- these effects observed in space-flown animals and astronauts mirrors Parkinson's disease (PD). Evidence of mitochondrial changes in space-flown human cells, examined through the lens of PD, suggests that spaceflight-induced PD-like molecular changes are important to monitor during deep space exploration. These changes, may potentially elevate the risk of PD in astronauts.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!